PHAXIAM Therapeutics

PHAXIAM Therapeutics is a French biotechnology company historically focused on developing bacteriophage-based treatments for bacterial infections, including pathogens associated with antimicrobial resistance. Formed in 2023 through the combination of Erytech Pharma and Pherecydes Pharma, its work has centered on phage-therapy research and development. The supplied website metadata appears unrelated to the company, so current operations and contact details should be independently verified.